CONTEXT: More than half the male population aged >50 yr have histologic evidence of benign prostatic hyperplasia (BPH), while prostate cancer (PCa) is among the most common male cancers according to recent registry data. Understanding the aetiologies of both conditions is crucial to reduce the resulting burden of mortality and morbidity. OBJECTIVE: This review aims to examine the available data on the epidemiology, pathology, risk factors, and genetic markers involved in BPH and PCa; to discuss their clinical implications for management of both conditions; and to discuss their implications for PCa prevention. Our primary objective was to clarify the relationship between BPH and PCa by bringing together evidence from diverse areas of research. EVIDENCE ACQUISITION: The primary source of data was PubMed, which was searched using Boolean strategies and by scanning lists of related articles. We also examined secondary sources from reference lists of retrieved articles and data presented at recent congresses. EVIDENCE SYNTHESIS: Accumulating evidence suggests that BPH and PCa share important anatomic, pathologic, and genetic links in addition to the well-established epidemiologic association between these conditions. We also found data that suggest interactions between apparently diverse factors, such as dihydrotestosterone levels and inflammation. Recent publications support the hypothesis that both BPH and PCa are part of the metabolic syndrome, while inflammation is emerging as a major contributor to the development of both BPH and PCa. Although many of the findings are preliminary and require further research, they offer new insight into the mechanisms of disease underlying the development of BPH and PCa. CONCLUSIONS: Available data suggest that epidemiologic and pathologic links exist between BPH and PCa. Evidence of links between the conditions and contributory factors may offer common preventative strategies for BPH and PCa and common therapeutic approaches to their management.
CONTEXT: More than half the male population aged >50 yr have histologic evidence of benign prostatic hyperplasia (BPH), while prostate cancer (PCa) is among the most common male cancers according to recent registry data. Understanding the aetiologies of both conditions is crucial to reduce the resulting burden of mortality and morbidity. OBJECTIVE: This review aims to examine the available data on the epidemiology, pathology, risk factors, and genetic markers involved in BPH and PCa; to discuss their clinical implications for management of both conditions; and to discuss their implications for PCa prevention. Our primary objective was to clarify the relationship between BPH and PCa by bringing together evidence from diverse areas of research. EVIDENCE ACQUISITION: The primary source of data was PubMed, which was searched using Boolean strategies and by scanning lists of related articles. We also examined secondary sources from reference lists of retrieved articles and data presented at recent congresses. EVIDENCE SYNTHESIS: Accumulating evidence suggests that BPH and PCa share important anatomic, pathologic, and genetic links in addition to the well-established epidemiologic association between these conditions. We also found data that suggest interactions between apparently diverse factors, such as dihydrotestosterone levels and inflammation. Recent publications support the hypothesis that both BPH and PCa are part of the metabolic syndrome, while inflammation is emerging as a major contributor to the development of both BPH and PCa. Although many of the findings are preliminary and require further research, they offer new insight into the mechanisms of disease underlying the development of BPH and PCa. CONCLUSIONS: Available data suggest that epidemiologic and pathologic links exist between BPH and PCa. Evidence of links between the conditions and contributory factors may offer common preventative strategies for BPH and PCa and common therapeutic approaches to their management.
Authors: O Kosti; L Goldman; D T Saha; R A Orden; A J Pollock; H L Madej; A W Hsing; L W Chu; J H Lynch; R Goldman Journal: Mutat Res Date: 2010-11-21 Impact factor: 2.433
Authors: Yiming Wang; Christian Gratzke; Alexander Tamalunas; Beata Rutz; Anna Ciotkowska; Frank Strittmatter; Annika Herlemann; Sophie Janich; Raphaela Waidelich; Chunxiao Liu; Christian G Stief; Martin Hennenberg Journal: Br J Pharmacol Date: 2016-11-01 Impact factor: 8.739
Authors: Amar Bhindi; Bimal Bhindi; Girish S Kulkarni; Robert J Hamilton; Ants Toi; Theodorus H van der Kwast; Andrew Evans; Alexandre R Zlotta; Antonio Finelli; Neil E Fleshner Journal: Can Urol Assoc J Date: 2017 Jan-Feb Impact factor: 1.862
Authors: Y Wang; T Kunit; A Ciotkowska; B Rutz; A Schreiber; F Strittmatter; R Waidelich; C Liu; C G Stief; C Gratzke; M Hennenberg Journal: Br J Pharmacol Date: 2015-05-05 Impact factor: 8.739
Authors: Katharina Boehm; Roger Valdivieso; Malek Meskawi; Alessandro Larcher; Maxine Sun; José Sosa; Audrey Blanc-Lapierre; Deborah Weiss; Markus Graefen; Fred Saad; Marie-Élise Parent; Pierre I Karakiewicz Journal: World J Urol Date: 2015-04-01 Impact factor: 4.226
Authors: Qingfeng Yu; Christian Gratzke; Yiming Wang; Annika Herlemann; Christian Maximilian Sterr; Beata Rutz; Anna Ciotkowska; Xiaolong Wang; Frank Strittmatter; Christian G Stief; Martin Hennenberg Journal: Br J Pharmacol Date: 2018-04-29 Impact factor: 8.739
Authors: Christopher J Weight; Simon P Kim; Debra J Jacobson; Michaela E McGree; Stephen A Boorjian; R Houston Thompson; Bradley C Leibovich; R Jeffrey Karnes; Jennifer St Sauver Journal: Eur Urol Date: 2013-01-04 Impact factor: 20.096